Felipe Arturo Morales Martínez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Felipe Arturo Morales Martínez has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Luis H. Sordia-Hernández
University Center for Reproductive Medicine Autonomous University of Nuevo León Monterrey México
2 shared publications - Otto H. Valdés-Martínez
University Center for Reproductive Medicine Autonomous University of Nuevo León Monterrey México
2 shared publications - Selene M. Garcia Luna
Department of Entomology, Texas A&M University, College Station, TX 77843, USA
2 shared publications Alejandro Aldape‐Arellano
SIMS IVF Clonskeagh Dublin Ireland
1 shared publicationAmanda Rojo‐Garza
Center for Advanced Analysis of Scientific Information Autonomous University of Nuevo León Monterrey México
1 shared publication- Andres Avalos-Bishop
Plataforma INVEST Medicina UANL-KER Unit Mayo Clinic (KER Unit Mexico), Universidad Autónoma de Nuevo León Facultad de Medicina, Monterrey, Mexico
1 shared publication
Latest Publications
- 1 December 2025
- Published by Colegio de Reproduccion Asistida de Mexico, S.C. in The Journal of Reproduction
- Vol. 3 (1) , 29-34
Pregnancy after treatment of an azoospermic male with adrenal congenital Hyperplas
A 31-year-old male with congenital adrenal hyperplasia (CAH) due to a 21-hydroxylase deficiency attended the Endocrinology Department of the University Hospital for fertility assessment. Physical examination was normal and the testicular ultrasound showed the presence of intra-testicular adrenal residues and normal testicular volume. The semen analysis reported azoospermia and was positive for a fructose qualitative test. As for the hormonal analysis, cortisol was within normal range, 17- alpha-hydroxyprogesterone (17-αOHP) and adrenocorticotropin (ACTH) were elevated while follicle-stimulating hormone (FSH), luteinizing hormone (LH) and total testosterone were low. Daily intake of 20 mg of oral hydrocortisone and 0.25 dexamethasone was initiated. After three months, the patient reported asthenia and decreased libido. Cortisol decreased close to normal levels, and 17-αOHP and ACTH also decreased although those did not reach normal levels. FSH and LH increased to normal range values. Androstenedione and prolactin were elevated. At this evaluation, the dehydroepiandrosterone (DHEA) was diminished at 27.4 mg/dl and the daily hydrocortisone dose was increased to 25 mg. After 5 months, cortisol decreased and 17-αOHP remained elevated, inhibin B was within the normal range at 51 pg/ml, and sperm cells were absent on the semen evaluation. The patient was referred to a reproductive biologist for azoospermia evaluation and management. The study of the female partner was normal regarding physical, hormonal, and tubal-uterine factors. To stimulate spermatogenesis, treatment with human chorionic gonadotropin (HCG) and human menopausal gonadotropin (HMG) was given for three months, but azoospermia persisted. Therefore, a testicular biopsy was obtained finding oligoasthenoteratozoospermia and testicular motile sperm were cryopreserved. His 34-year-old female partner was subject to controlled ovarian stimulation with a subcutaneous injection of Human recombinant follicle-stimulating hormone (r-FSH). When at least three follicles reached ≥ 18 mm, the oocyte maturation was co-triggered by 250 UI of choriogonadotropin subcutaneously and follicular aspiration occurred 36 hours later. A total of 20 oocytes were retrieved from which 10 metaphase II oocytes were used for the intracytoplasmic sperm injection (ICSI), and half of them fertilized. Meanwhile, endometrial preparation began for frozen embryo transfer (FET) on day 1 of the menstrual cycle, with 6 mg of estradiol valerate orally for 12 days, after ultrasonography confirmed adequate endometrial thickness, 600 mg per day of vaginal progesterone was administrated 4 days prior the embryo transfer, at which time, two embryos on cleavage stage (day 3) were transferred with a positive pregnancy test two weeks later. The results of the molecular analysis reported a CAH-heterozygous carrier status of the mother so glucocorticoid therapy was started. A non-invasive
- 1 December 2025
- Published by Colegio de Reproduccion Asistida de Mexico, S.C. in The Journal of Reproduction
- Vol. 3 (1) , 29-34
Pregnancy after treatment of an azoospermic male with adrenal congenital Hyperplas
A 31-year-old male with congenital adrenal hyperplasia (CAH) due to a 21-hydroxylase deficiency attended the Endocrinology Department of the University Hospital for fertility assessment. Physical examination was normal and the testicular ultrasound showed the presence of intra-testicular adrenal residues and normal testicular volume. The semen analysis reported azoospermia and was positive for a fructose qualitative test. As for the hormonal analysis, cortisol was within normal range, 17- alpha-hydroxyprogesterone (17-αOHP) and adrenocorticotropin (ACTH) were elevated while follicle-stimulating hormone (FSH), luteinizing hormone (LH) and total testosterone were low. Daily intake of 20 mg of oral hydrocortisone and 0.25 dexamethasone was initiated. After three months, the patient reported asthenia and decreased libido. Cortisol decreased close to normal levels, and 17-αOHP and ACTH also decreased although those did not reach normal levels. FSH and LH increased to normal range values. Androstenedione and prolactin were elevated. At this evaluation, the dehydroepiandrosterone (DHEA) was diminished at 27.4 mg/dl and the daily hydrocortisone dose was increased to 25 mg. After 5 months, cortisol decreased and 17-αOHP remained elevated, inhibin B was within the normal range at 51 pg/ml, and sperm cells were absent on the semen evaluation. The patient was referred to a reproductive biologist for azoospermia evaluation and management. The study of the female partner was normal regarding physical, hormonal, and tubal-uterine factors. To stimulate spermatogenesis, treatment with human chorionic gonadotropin (HCG) and human menopausal gonadotropin (HMG) was given for three months, but azoospermia persisted. Therefore, a testicular biopsy was obtained finding oligoasthenoteratozoospermia and testicular motile sperm were cryopreserved. His 34-year-old female partner was subject to controlled ovarian stimulation with a subcutaneous injection of Human recombinant follicle-stimulating hormone (r-FSH). When at least three follicles reached ≥ 18 mm, the oocyte maturation was co-triggered by 250 UI of choriogonadotropin subcutaneously and follicular aspiration occurred 36 hours later. A total of 20 oocytes were retrieved from which 10 metaphase II oocytes were used for the intracytoplasmic sperm injection (ICSI), and half of them fertilized. Meanwhile, endometrial preparation began for frozen embryo transfer (FET) on day 1 of the menstrual cycle, with 6 mg of estradiol valerate orally for 12 days, after ultrasonography confirmed adequate endometrial thickness, 600 mg per day of vaginal progesterone was administrated 4 days prior the embryo transfer, at which time, two embryos on cleavage stage (day 3) were transferred with a positive pregnancy test two weeks later. The results of the molecular analysis reported a CAH-heterozygous carrier status of the mother so glucocorticoid therapy was started. A non-invasive
- 20 June 2025
- Published by Wiley in International Journal of Gynecology & Obstetrics
- Vol. 171 (3) , 1168-1179
Efficacy of medical and surgical interventions to reduce blood loss during laparoscopic myomectomy: A systematic review and meta‐analysis
Objectives: To compare the effectiveness of different medical and surgical interventions to reduce blood loss in milliliters during laparoscopic myomectomy and to assess the total operative time, as well as the need for conversion to hysterectomy or laparotomy. Search Strategy: An exhaustive search was conducted across the following databases, MEDLINE, EMBASE, PubMed, Web of Science and Scopus, from the first year available until May 2022. Terms used were myomectomy, fibroid, fibroid resection, laparoscopy, endoscopy, gynecologic endoscopy, blood loss, hemorrhage, and transfusion. Selection Criteria: Randomized controlled trials involving patients with uterine myomatosis who underwent laparoscopic myomectomy and received either a specific pharmacologic or surgical intervention to reduce blood loss, compared with another intervention or placebo, were included. Data Collection and Analysis: Data extraction was performed by two authors using a previously designed form. Effect sizes for each treatment comparison reported were calculated as mean differences, and a frequentist network meta‐analysis was performed for the outcome of serum hemoglobin levels using the control group as the comparator. Main Results: A total of 23 studies were included for the quantitative synthesis, with 2152 women. The combination of bupivacaine with epinephrine showed the most beneficial effect on hemoglobin decrease (in mg/dL) in the network meta‐analysis. Among the mechanical measures, the temporary uterine artery ligation with or without ovarian vessel ligation demonstrated the greatest reduction in blood loss (mean difference [MD] −122.61, 95% confidence interval [CI] −156.3 to −88.49; MD −95.14, 95% CI −113.17 to −77.10, with or without ligation, respectively). Conclusions: Different interventions can reduce blood loss during laparoscopic myomectomy, the most effective were epinephrine plus bupivacaine and temporary uterine artery ligation. Using them is critical for minimizing complications during the procedure and so allowing fertility preservation. However, further randomized controlled trials are required to safely establish clinical recommendations. Clinical Registration: Prospective Registry of Systematic Reviews (PROSPERO) ID: CRD42022324210.
- 20 June 2025
- Published by Wiley in International Journal of Gynecology & Obstetrics
- Vol. 171 (3) , 1168-1179
Efficacy of medical and surgical interventions to reduce blood loss during laparoscopic myomectomy: A systematic review and meta‐analysis
Objectives: To compare the effectiveness of different medical and surgical interventions to reduce blood loss in milliliters during laparoscopic myomectomy and to assess the total operative time, as well as the need for conversion to hysterectomy or laparotomy. Search Strategy: An exhaustive search was conducted across the following databases, MEDLINE, EMBASE, PubMed, Web of Science and Scopus, from the first year available until May 2022. Terms used were myomectomy, fibroid, fibroid resection, laparoscopy, endoscopy, gynecologic endoscopy, blood loss, hemorrhage, and transfusion. Selection Criteria: Randomized controlled trials involving patients with uterine myomatosis who underwent laparoscopic myomectomy and received either a specific pharmacologic or surgical intervention to reduce blood loss, compared with another intervention or placebo, were included. Data Collection and Analysis: Data extraction was performed by two authors using a previously designed form. Effect sizes for each treatment comparison reported were calculated as mean differences, and a frequentist network meta‐analysis was performed for the outcome of serum hemoglobin levels using the control group as the comparator. Main Results: A total of 23 studies were included for the quantitative synthesis, with 2152 women. The combination of bupivacaine with epinephrine showed the most beneficial effect on hemoglobin decrease (in mg/dL) in the network meta‐analysis. Among the mechanical measures, the temporary uterine artery ligation with or without ovarian vessel ligation demonstrated the greatest reduction in blood loss (mean difference [MD] −122.61, 95% confidence interval [CI] −156.3 to −88.49; MD −95.14, 95% CI −113.17 to −77.10, with or without ligation, respectively). Conclusions: Different interventions can reduce blood loss during laparoscopic myomectomy, the most effective were epinephrine plus bupivacaine and temporary uterine artery ligation. Using them is critical for minimizing complications during the procedure and so allowing fertility preservation. However, further randomized controlled trials are required to safely establish clinical recommendations. Clinical Registration: Prospective Registry of Systematic Reviews (PROSPERO) ID: CRD42022324210.
- Open Access
- 1 January 2019
- Published by GN1 Sistemas e Publicacoes Ltd. in JBRA Assisted Reproduction
- Vol. 23 (2) , 112-116
The elimination of apoptotic sperm in IVF procedures and its effect on pregnancy rate
To identify the effect of apoptotic sperm elimination with MACS in patients that require IVF. An experimental, cross-sectional, descriptive, prospective and non-blinded study of diagnostic tests performed in patients who required IVF and ICSI from July 2011 to July 2012. Ninety-two couples participated according to the treatment administered to the semen sample; in the control group: the samples were subjected only to density gradients before ICSI, in the study group: the same procedure was performed plus the addition of the MACS technique. Comparing the groups, we assessed the fertilization, division, viable embryos and clinical pregnancy rates in all cases. We found significant differences when using MACS technique in sperm parameters. We found no differences between the total samples of the control and study groups. When separating the own and donated eggs in each group, we found an improvement in the fertilization rates (p<0.001) of the own eggs. In both groups, the handling of donated eggs lead to a significant improvement in the immunological pregnancy test (IPT) and fetal heart rate (FHR) results. Only in the donated eggs group, where MACS was applied, could we see that all cases with positive IPT had a fetal heart rate, which shows a significant difference (p<0.002) when compared with the control group, where the percentage decreased abruptly. This study demonstrates the effectiveness of the use of annexins (MACS) in eliminating apoptotic sperm, and when the obtained sperm is applied to good-quality eggs.
- 1 January 2019
- Published by GN1 Sistemas e Publicacoes Ltd. in JBRA Assisted Reproduction
- Vol. 23 (2) , 112-116
Open AccessThe elimination of apoptotic sperm in IVF procedures and its effect on pregnancy rate
To identify the effect of apoptotic sperm elimination with MACS in patients that require IVF. An experimental, cross-sectional, descriptive, prospective and non-blinded study of diagnostic tests performed in patients who required IVF and ICSI from July 2011 to July 2012. Ninety-two couples participated according to the treatment administered to the semen sample; in the control group: the samples were subjected only to density gradients before ICSI, in the study group: the same procedure was performed plus the addition of the MACS technique. Comparing the groups, we assessed the fertilization, division, viable embryos and clinical pregnancy rates in all cases. We found significant differences when using MACS technique in sperm parameters. We found no differences between the total samples of the control and study groups. When separating the own and donated eggs in each group, we found an improvement in the fertilization rates (p<0.001) of the own eggs. In both groups, the handling of donated eggs lead to a significant improvement in the immunological pregnancy test (IPT) and fetal heart rate (FHR) results. Only in the donated eggs group, where MACS was applied, could we see that all cases with positive IPT had a fetal heart rate, which shows a significant difference (p<0.002) when compared with the control group, where the percentage decreased abruptly. This study demonstrates the effectiveness of the use of annexins (MACS) in eliminating apoptotic sperm, and when the obtained sperm is applied to good-quality eggs.